Eli Lilly's Q2 revenue grew 36% year-on-year, exceeding expectations. The company also plans to launch more new products and expand sales of existing products in the second half of the year.

FDA approved Eli Lilly and Company's Alzheimer's drug Kinsula for commercialization in the U.S. market.

Lilly's fourth-quarter financials beat Wall Street expectations, boosted by the successful launch of new weight-loss drug Zepbound and strong sales of diabetes treatment Mounjaro。